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ORIGINAL ARTICLE
Quantitative proteomics of delirium cerebrospinal ﬂuid
A Poljak1,2,3, M Hill2, RJ Hall4, AM MacLullich4, MJ Raftery1, J Tai2, S Yan2 and GA Caplan5,6
Delirium is a common cause and complication of hospitalization in older people, being associated with higher risk of future
dementia and progression of existing dementia. However relatively little data are available on which biochemical pathways are
dysregulated in the brain during delirium episodes, whether there are protein expression changes common among delirium
subjects and whether there are any changes which correlate with the severity of delirium. We now present the ﬁrst proteomic
analysis of delirium cerebrospinal ﬂuid (CSF), and one of few studies exploring protein expression changes in delirium. More than
270 proteins were identiﬁed in two delirium cohorts, 16 of which were dysregulated in at least 8 of 17 delirium subjects compared
with a mild Alzheimer’s disease neurological control group, and 31 proteins were signiﬁcantly correlated with cognitive scores
(mini-mental state exam and acute physiology and chronic health evaluation III). Bioinformatics analyses revealed expression
changes in several protein family groups, including apolipoproteins, secretogranins/chromogranins, clotting/ﬁbrinolysis factors,
serine protease inhibitors and acute-phase response elements. These data not only provide conﬁrmatory evidence that the
inﬂammatory response is a component of delirium, but also reveal dysregulation of protein expression in a number of novel and
unexpected clusters of proteins, in particular the granins. Another surprising outcome of this work is the level of similarity of CSF
protein proﬁles in delirium patients, given the diversity of causes of this syndrome. These data provide additional elements for
consideration in the pathophysiology of delirium as well as potential biomarker candidates for delirium diagnosis.
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INTRODUCTION
Delirium is a common cause and complication of hospitalization,
particularly prevalent in the elderly and within intensive care units.
Although it is an acute condition from which most patients
recover, it is also associated with multiple adverse outcomes
including higher risk of future dementia as well as progression of
existing dementia and higher mortality.1–3 The aetiology of
delirium is thought to involve neurotransmitter changes arising
from diverse sources including hypoxaemia, metabolic derange-
ments, disturbance of the sleep–wake cycle, drug effects or
systemic inﬂammation.4,5 However there is a paucity of data
relating to biochemical changes in delirium cerebrospinal ﬂuid
(CSF).6 There is much speculation; however, little evidence is
available on which biochemical pathways are dysregulated in the
brain during delirium episodes, whether there are protein
expression changes common among delirium subjects and
whether there are protein changes which correlate with delirium
severity. Further, there is no available biochemical test which
could facilitate delirium detection. Quantitative proteomics using
iTRAQ tags is a well-established discovery-based tool, which
allows unbiased evaluation of dysregulated protein expression in
complex biological samples such as cellular and tissue extracts
and body ﬂuids. It has wide application in the biological and
biomedical sciences and is increasingly applied to the study of
neurodegenerative diseases such as Alzheimer’s disease (AD).7–9
However, to date, few studies of delirium have utilized proteomics
approaches.10,11 None have utilized CSF which is the body ﬂuid
most likely to reﬂect biochemical changes in conditions which
disrupt central nervous system function, and only one proteomics
study has been reported on delirium subjects.10 This study utilized
urine from post-cardiac surgery intensive care unit subjects, and
applied MALDI-TOF mass spectrometric proﬁling to the intact
proteins, which provided some quantitative data but precluded
sequence identiﬁcation. Furthermore few proteins were quanti-
ﬁed, none of which were delirium speciﬁc. Another proteomics
study of delirium plasma is in the planning phase,11 and will utilize
SELDI-TOF, which is typically used for proteomics proﬁling, but will
preclude protein sequence identiﬁcation. In the current study, we
used CSF samples from delirium subjects and neurological
controls (Sydney study group),12 to identify proteins with altered
expression levels relative to a mild dementia control group. We
then validated the observed changes using a second study group
based in Edinburgh (Edinburgh study group). Dysregulated
proteins were analysed using bioinformatics tools DAVID and
STRING to determine if functional relationships would emerge.
This approach provides both protein sequence identiﬁcation and
quantiﬁcation of relative protein expression changes, facilitating
quantiﬁcation of potential biomarkers and a better understanding
of the pathology at a molecular level.
MATERIALS AND METHODS
Subjects
Sydney study. Patients admitted to the Geriatric Medicine Unit at the
Prince of Wales Hospital were screened for delirium in the Emergency
Department,12,13 where they were admitted for a variety of medical
diagnoses triggering the delirium, including infections, metabolic pro-
blems and adverse drug reactions, but on average were suffering from at
least two identiﬁable causes of delirium, and on the Geriatric Medicine
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ward after admission from the Emergency Department, which is the source
of 99% of Geriatric Medicine ward patients in our hospital. As part of the
standard clinical care in this unit, patients suffering from delirium, not
resolving after more than 5 days of treatment, are considered for
additional investigations, including lumbar puncture. This procedure is
discussed with their ‘person responsible’ or substitute decision maker, and
the patient where possible, who gave written consent. For the purposes of
this study, a portion of the CSF obtained from hospitalized patients with
current delirium for clinical purposes, was stored. Patients with delirium
had mild-to-moderate levels of disorder on the basis of the delirium index
score (DIS;14 Table 1 and Supplementary Table 2). Delirium severity was
based on scores on the delirium index,14 and this was the severity scale
measure used for comparison with proteomics data. Baseline assessment
of the patients with delirium in the Sydney cohort also included; CAM
(confusion assessment method),15 IQCODE (informant questionnaire on
cognitive decline in the elderly); Barthel Index,16 modiﬁed instrumental
activities of daily living index,17 acute physiology and chronic health
evaluation III (APACHE III)18 and the Charlson comorbidity index.19 CSF was
also obtained from neurological control subjects (AD with no delirium)
where the patient and their ‘person responsible’ consented to enter the
study. Patients in the control group were from our outpatient clinic
without any evidence of current delirium. They were diagnosed with
dementia on the basis of the Diagnostic and Statistical Manual, 4th
edition20 and the National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and Related Disorders
Association criteria.21 AD subjects had mild-to-moderate levels of disorder
on the basis of the mini-mental state exam (MMSE).22
Edinburgh study. To ascertain whether dysregulated protein expression
would show similar trends across studies, an independent study group
based in Edinburgh was used. Community-dwelling patients over the age
of 60 with acute hip fracture were recruited on the Orthopaedic Trauma
Unit of the New Royal Inﬁrmary of Edinburgh. They were assessed for
delirium pre-operatively and daily postoperatively until day 4, and further
on day 7 and between days 10–14. Precipitants of delirium included
trauma, pain, medication, in particular, opiate analgesia and anaesthetic
agents, and infection. CSF was obtained at the onset of spinal anaesthetic
for the operation to repair their hip fracture.23,24 Baseline assessment of
the Edinburgh cohort included MMSE, pre- and postoperative Delirium
Rating Scale—revised—98 (DRS-R98)25,26 APACHE II index,27 IQCODE28 and
Lawton instrumental activities of daily living.17 Delirium severity was based
on scores on the Delirium Rating Scale—revised—98 (DRS-R98),25,26 and
this was the severity scale measure used for comparison with proteomics
data. Demographics for the study groups as well as test scores are shown
in Supplementary Tables 1 and 2.
Ethics approval was obtained from the Human Research Ethics
Committee of the South Eastern Sydney Health Area (eastern section)
and the University of New South Wales Ethics Committee. The proposal
was also reviewed by the NSW Guardianship Tribunal that has to approve
interventional studies involving participants who are unable to give
consent, but not observational studies, and no objections were raised. The
Edinburgh study was approved by the Scotland A Research Ethics
Committee.
CSF collection and total protein assay
CSF samples were collected from the Sydney study group by lumbar
puncture on the ward or under X-ray guidance, using local anaesthetic but
no sedation or restraining devices and from the Edinburgh study group by
lumbar puncture administered to induce spinal anaesthesia for the repair
of their neck of femur fracture. CSF samples were transported from
Edinburgh to Sydney on dry ice and all laboratory-based experiments
using both cohorts, including proteomics, enzyme-linked immunosorbent
assay (ELISA) and total protein assay, were carried out in the Bioanalytical
Mass Spectrometry Facility, School of Medical Sciences, University of New
South Wales. The CSF was centrifuged, aliquoted and stored at − 80 °C until
required. The total protein level of CSF samples was assayed using the
bicinchoninic acid assay purchased from Pierce (Sydney, NSW, Australia)
and following the manufacturer’s instructions exactly. Bovine serum
albumin was used to construct the standard curve (0.025–2mgml− 1
concentration range, triplicate standards), and the absorbance read at a
wavelength of 595 nm. A third-order polynomial curve was ﬁtted, with an
r2 typically 40.99 and the equation used to calculate protein concentra-
tions in CSF.
iTRAQ, two-dimensional liquid chromatography-tandem mass
spectrometry and data analysis
Isobaric labelling using iTRAQ reagents, two-dimensional liquid
chromatography-tandem mass spectrometry and data analysis were
performed according to published approaches.7,29–31 An 8-plex iTRAQ
design was used, which represents the maximum number of iTRAQ
isobaric tag reagents available for any single experiment. With 17 delirium
subjects and additional controls, a minimum of three iTRAQ experiments
were therefore required (experiments 1 and 2 using Sydney study subjects
and experiment 3 using Edinburgh study subjects). The experimental
design is outlined in Supplementary Table 2, showing which iTRAQ tag was
Table 1. Baseline characteristics of Sydney and Edinburgh Delirium Study groups
Sydney Delirium Study Delirium, mean+s.d. Dementia, mean+s.d. P-valuea
Age 80.3± 9.0 83.1± 5.8 0.364
Sex (F:M) 4:8 9:6 0.161
Mini-mental state exam (/30) 15.6± 4.4 21.5± 4.6 0.008
Informant questionnaire on cognitive decline (/5) 4.0± 0.6 3.7± 0.4 0.078
Confusion assessment method 6.1± 1.3 0.0± 0.0 o0.001
Delirium index 15.6± 4.8 2.9± 1.4 o0.001
APACHE III (acute physiology and chronic health evaluation III) index 47.6± 23.2 30.6± 3.6 0.028
Geriatric Depression Scale (/15) 5.6± 1.4 6.7± 2.5 0.248
Barthel score (/20) 17.4± 3.8 19.1± 1.8 0.186
Instrumental activities of daily living (/12) 6.1± 4.1 8.5± 2.7 0.100
Charlson comorbidity index 6.25± 2.5 6.4± 2.9 0.920
Edinburgh Delirium Study Delirium, mean+s.d. Normal controls, mean+s.d. P-value
Age 83.6± 10.1 81.1± 10.84 0.685
Sex (F:M) 3:2 7:1 0.640
Mini-mental state exam (/30)b 19.6± 10.5 26.9± 1.8 0.198
Informant questionnaire on cognitive decline (/5) 3.3± 0.4 3.1± 0.1 0.289
Postoperative DRS-R98b 19.6± 9.1 5.3± 1.9 0.025
APACHE II (acute physiology and chronic health evaluation II) index6 9.4± 2.3 7.3± 1.2 0.11
Lawton instrumental activities of daily living 5.2± 2.3 6.9± 1.1 0.19
aAll demographics data were compared using a two-tailed t-test, except for sex distribution, which was tested using the Fisher's exact test variant of the χ2.
bPostoperative day 1 MMSE and DRS-R98 are shown here for the Edinburgh delirium study.
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used for each subject. The 119 iTRAQ tag in each experiment was the mild
AD control, which was used as the denominator for all iTRAQ ratios in both
the Sydney and Edinburgh groups to facilitate comparison across groups.
A detailed description of sample preparation and liquid chromatography-
tandem mass spectrometry analysis is provided in the Supplementary
Section.
ELISA assay of α-1-acid glycoprotein 1
To partially validate the iTRAQ proteomics data using an independent
method, an ELISA was carried out using additional delirium18 and AD12
subjects from the Sydney cohort. An Assaypro AGP ELISA kit speciﬁc for
human α-1-acid glycoprotein (Saint Charles, MO, USA) was used, following
the manufacturer’s instructions. This assay has a detection limit of ~ 0.06
μgml− 1 and intra- and inter-assay CV% of 4.7 and 7.3, respectively. CSF
samples were diluted (1:100) using the kit mix diluent before assay. All data
used for statistical analysis fell within the range of the standard curve. Log
data were used for both concentration and absorbance values, and a third-
order polynomial curve was ﬁtted to the standards (r2 = 0.997), with a
concentration range of 0.063–4 μgml− 1.
Statistics and bioinformatics; DAVID and STRING analyses
SPSS 20 was used to perform the Levine’s test and t-test analyses of the
alpha-1-acidic glycoprotein ELISA data, and to compare basal character-
istics of the delirium vs dementia or delirium vs no delirium subjects in the
Sydney and Edinburgh study groups, respectively. The Fisher’s exact test
variant of the χ2 was used to compare ratios of male to female subjects.
The list of proteins deregulated in delirium relative to mild dementia which
were identiﬁed by ProteinPilot analysis were further evaluated using WEB-
based bioinformatics tools DAVID v6.7refs 32,33 and STRING v9.05.34 DAVID
software determines whether statistically signiﬁcant enrichment of speciﬁc
protein functional clusters occurs within a target group of proteins relative
to a control group (we used the full human genome as control). The
STRING clustering tool was used to explore currently known associations
between proteins, indicated in the scientiﬁc literature. However in the
absence of literature-based evidence for speciﬁc connections, some
proteins may miss inclusion in a cluster. Therefore in addition to using
the clustering function, the STRING tool was used to explore enrichment of
biological processes, molecular functions, cellular components and KEGG
pathways. Signiﬁcance of enrichment was based on a P-value of at least
0.05 using FDR correction. The regression analysis tool in the Microsoft XL
data analysis package was used to perform regression analysis on iTRAQ
scores vs MMSE, APACHE III and DIS values.
RESULTS
Group demographics
The subject demographics are shown in Table 1. There were 17
delirium, 17 AD and 8 normal control subjects used for iTRAQ
experiments. Psychometric performance of the Sydney cohort of
delirium and dementia subjects signiﬁcantly differed on four
instruments (Table 1 and Supplementary Table 2); MMSE (in which
dementia subject scores were signiﬁcantly higher than those of
delirium subjects), CAM, DIS and APACHE III Index, in all three of
which delirium subjects had higher scores than dementia subjects
(Supplementary Table 2). In the Edinburgh study, the delirium
subjects had a lower mean MMSE score and higher postoperative
DRS-R98 and APACHE II scores relative to controls, however, only
the postoperative DRS-R98 scores were signiﬁcantly different
(P= 0.025).
Summary of iTRAQ experiment outcomes
A total of 273 proteins were identiﬁed in three separate iTRAQ
experiments (Supplementary Table 4), of which 89 were common
to all three experiments. Approximately 12% had dysregulated
protein expression in a minimum of eight subjects, however, many
had dysregulated expression in just a few delirium patients
(Figure 1). In two iTRAQ experiments, comprising subjects from
the Sydney group, 26 proteins had dysregulated protein expres-
sion in at least 50% of delirium subjects relative to the mild AD
neurological control group (Supplementary Table 3). When all
three iTRAQ experiments were compared, comprising both the
Sydney and Edinburgh groups, 16 proteins had dysregulated
protein expression in eight or more subjects with delirium, across
all three iTRAQ experiments and across both study groups
(Table 2). Direction of expression change was the same for a
few proteins, but most often a mixture of responses was observed
(Table 2). Proteins with altered expression in at least 4 out of 17
delirium subjects were processed using the DAVIDv6.7 and
STRING v9.05 bioinformatics tools to identify enrichment in
speciﬁc functions (Supplementary Tables 1 and 5). Statistically
signiﬁcant enrichment in a variety of biological functions was
identiﬁed, some of which were sample related, such as secreted
and plasma proteins, but all the remaining clusters reﬂected
speciﬁc functions, such as responses to wounding, inorganic
substances and external stimulus, regeneration, protease inhibi-
tion, acute-phase response and high-density lipoprotein particle.
Expression changes of speciﬁc proteins
Proteins with altered expression levels in the majority of delirium
subjects (Table 2) included alpha-1-antitrypsin (SERPINA3) and
alpha-1-acid glycoprotein 1 (ORM1), both of which were
upregulated in the majority of delirium subjects. Several proteins
were signiﬁcantly downregulated in the majority of subjects,
including secretogranin-1 (CHGB), apolipoprotein E (APOE),
clusterin (CLU)—also known as apolipoprotein J and apolipopro-
tein A1 (APOA1). Subsequent bioinformatics analyses using
STRING and DAVID software only included proteins with
signiﬁcantly altered expression level in at least 4 out of 17 of
the delirium subjects. The MCL clustering function of the STRING
Figure 1. Proteins identiﬁed in the three iTRAQ experiments from
two studies (Sydney Delirium Study and Edinburgh Delirium Study),
and a total of 17 subjects with either mild or moderate-to-severe
delirium are shown. All proteins were identiﬁed with a conﬁdence of
95% or greater (unused score of ⩾ 1.3 in ProteinPilot v3.0), were
based on 4–7 iTRAQ technical replicates and signiﬁcantly dysregu-
lated proteins were identiﬁed at the P⩾ 0.05 level. (a) Total numbers
of unique proteins identiﬁed in any of the three experiments,
proteins identiﬁed in all three experiments and numbers of
dysregulated proteins identiﬁed in 1–3, 4–7 or ⩾ 8 subjects are
shown. (b) Percentage of proteins identiﬁed in all three experiments
and dysregulated in 1–3, 4–7 or ⩾ 8 subjects. The list of proteins
dysregulated in eight or more delirium subjects, and which are
identiﬁed in all three iTRAQ experiments are shown in Table 2.
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v9.05 bioinformatics analysis tool identiﬁed four clusters, broadly
representing; granins, haptoglobin/haemoglobin complex, serpins
and apolipoproteins (Figure 2a). Not all signiﬁcantly deregulated
proteins formed part of a STRING cluster, because literature
evidence for an association is currently lacking. However some-
times non-clustered proteins are structurally or functionally linked
to proteins which have formed part of a cluster. For example, in
Figure 2a, SERPINS A1, C1 and F1 are clustered, but SERPIN A3 is
not. Similarly NCAM1 is clustered but NRCAM is not. It is very likely
that these related proteins may be involved in similar processes,
and our data set provides a good rationale for further investiga-
tion. Other proteins such as FAM3C and SPARCL1 do not cluster
with any of the other proteins in the set, and for these it remains
to be seen whether connections will emerge or if their links to
delirium will be through other proteins and pathways, as yet not
identiﬁed here. The clustering function has not identiﬁed direct
connections for all the proteins; however, the STRING enrichment
tool has identiﬁed biological process, molecular function, cellular
component and/or KEGG pathway enrichment for all of the
proteins (Supplementary Tables 5 and 6). This offers insight into
the roles that particular protein groups may have, some of which
include platelet degranulation/activation, response to wounding,
inﬂammation, coagulation, enzyme activity, biological regulation,
cholesterol and lipoprotein processing, neuronal regeneration and
extracellular vesicle components (Supplementary Tables 5 and 6).
Table 2. Proteins identiﬁed in three iTRAQ experiments from two independent studies (Sydney Delirium Study and Edinburgh Delirium Study), with
a total of 17 subjects with either mild or moderate-to-severe delirium
Unused % Cov (95) Accession Peptides (95%) 113:119 114:119 115:119 116:119 117:119 118:119 121:119
31.98 49.75 47 1.013 2.268 1.996 1.245 1.312 1.261 1.179
36.34 40.30 884 926.1 41 1.514 1.435 1.231 2.570 1.988 1.246 0.727
38.51 51.74 49 1.214 1.299 1.544 1.666 1.210 1.548 1.116
38.88 51.19 30 1.311 2.185 0.782 0.917 1.143 0.917 1.075
52.71 52.62 641 737.1 41 0.578 0.980 1.120 3.523 1.417 1.040 1.258
47.98 51.43 39 1.439 1.739 1.187 0.564 0.576 0.746 1.008
118.53 72.49 179 1.042 0.915 0.968 0.993 1.438 1.277 1.236
121.09 73.21 224 63.1 128 1.008 0.996 1.187 0.737 0.868 0.967 0.941
109.61 65.76 127 1.209 1.659 1.614 1.293 1.452 1.000 1.041
37.42 45.76 29 0.866 1.495 1.548 1.022 1.142 1.135 1.016
43.51 49.11 550 991.3 33 1.264 1.393 0.761 2.296 1.691 1.227 0.789
43.87 56.25 46 0.875 1.099 0.647 1.275 0.768 0.706 0.732
15.79 10.97 8 1.014 1.439 1.233 1.209 1.119 1.161 1.183
32.84 19.98 21 885.1 22 1.513 1.138 0.971 1.819 2.827 0.953 0.854
22.59 17.09 15 1.088 1.195 1.005 1.326 0.834 0.937 0.869
83.05 61.48 76 0.863 1.368 1.466 0.796 1.030 1.090 0.916
87.06 68.42 553 177.1 78 1.312 1.302 0.967 1.941 1.288 1.256 0.845
84.68 63.40 103 0.895 0.888 0.790 1.060 0.619 1.319 0.741
179.93 61.15 104 0.996 1.094 0.991 1.009 1.158 1.171 1.182
157.69 52.56 783 987.2 89 1.050 0.885 0.949 1.085 1.173 1.070 1.020
157.97 52.19 129 1.180 1.077 1.161 0.981 1.036 1.132 1.057
98.18 43.15 61 0.994 0.910 0.968 0.909 1.110 1.083 1.037
97.82 43.42 478 003.2 57 1.185 0.907 0.863 1.200 1.187 1.039 1.272
106.58 46.20 90 1.332 0.799 0.862 0.714 0.988 1.106 0.878
35.14 93.88 42 1.011 0.356 1.119 0.427 0.346 1.065 0.731
92.49 93.88 654 755.3 145 0.859 0.896 1.052 0.792 16.619 1.465 11.919
57.45 93.88 87 1.469 0.708 1.058 0.724 0.609 7.495 0.842
21.21 58.45 47 0.945 0.460 1.184 0.614 0.359 0.899 0.816
79.61 92.96 410 714.5 161 0.849 0.906 1.057 0.842 13.371 1.461 10.099
64.75 91.55 133 1.462 0.496 0.802 0.541 0.451 9.690 0.837
24.54 43.33 15 1.007 0.703 0.972 1.034 1.413 1.245 1.307
17.38 27.35 290 315.4 9 1.157 0.686 0.717 0.781 1.269 0.888 0.853
26.67 44.86 20 0.642 0.986 0.631 0.691 1.130 0.495 0.836
18.93 19.66 10 1.126 0.818 1.434 1.039 1.487 1.284 1.370
12.25 17.74 292 071.6 6 0.964 0.745 0.794 0.833 0.932 0.932 0.728
32.68 44.23 17 0.772 0.914 0.732 0.850 0.917 0.723 1.039
36.33 32.94 25 1.167 0.800 1.093 1.087 1.235 1.098 1.343
29.08 26.44 6601.5 20 0.913 0.560 0.724 0.739 0.728 0.741 0.644
51.65 45.79 51 0.460 0.686 0.529 0.706 0.827 0.501 0.777
40.29 58.36 23 0.848 0.722 1.156 1.172 1.390 0.992 1.141
37.12 58.36 21 842.1 24 0.903 0.585 0.893 0.850 0.779 0.821 0.735
46.10 60.57 39 0.668 0.750 0.698 0.799 0.874 0.547 1.120
38.43 34.13 34 0.886 0.792 0.880 1.055 0.838 0.945 1.011
36.14 31.94 400 826.1 35 0.775 0.941 0.909 0.694 1.536 0.891 1.162
55.71 39.72 55 0.901 0.743 0.481 0.785 0.579 0.939 0.895
42.61 67.79 36 0.852 1.040 0.621 0.771 0.751 0.945 0.793
35.96 52.43 218 41.1 31 0.769 0.736 0.919 1.004 0.693 0.809 1.299
62.06 77.15 60 0.968 0.643 0.693 0.955 0.506 1.233 0.681
iTRAQ reporter ion ratios (all relative to 119 reporter = mild AD (no delirium) control)
Moderate delirium Mild delirium
Name
ORM1 alpha-1-acid glycoprotein 1 precursor
HP haptoglobin
TF serotransferrin
SERPINA3 similar to alpha-1-antichymotrypsin
FGA isoform 1 of fibrinogen alpha chain
SERPINA1 isoform 1 of alpha-1-antitrypsin
C3 complement C3 (fragment)
A2M alpha-2-macroglobulin
HBB hemoglobin subunit beta
HBA1;HBA2 hemoglobin subunit alpha
CHGA chromogranin-A
SCG3 secretogranin-3
CHGB secretogranin-1
APOE apolipoprotein E
CLU isoform 2 of clusterin
APOA1 apolipoprotein A-I
Delirium severity was determined by scores on scales designed to measure delirium severity, and were the Delirium Index and Delirium Rating Scale-R98 in the
Sydney and Edinburgh studies respectively. Data were analysed using ProteinPilot v3.0.0, and using the ipi.HUMAN.v3.58 database. The denominator in each
case is the 119 iTRAQ tag, representing the mild AD-pooled neurological control group (Sydney Delirium Study), being the single constant sample used in all
three experiments. The list of proteins with signiﬁcantly dysregulated expression in eight or more delirium subjects, and which are identiﬁed in all three iTRAQ
experiments are shown. Signiﬁcantly upregulated proteins are highlighted in pink and signiﬁcantly downregulated proteins are highlighted in blue (P⩽ 0.05),
the boxes with no colour being nonsigniﬁcantly different. The orange bars represent data from the Edinburgh Delirium Study and the yellow and green bars
represent data from the two Sydney Delirium Study experiments. There is almost complete overlap between the proteins identiﬁed in this table and the
Supplementary Table 3 data (Supplementary Information), indicating commonality of protein dysregulation. aThese samples correspond to the reporter ions
used in the Edinburgh Delirium Study iTRAQ experiment (orange bars). bThese samples correspond to the reporter ions used in each of the two Prince of
Wales Delirium Study iTRAQ experiments (yellow and green bars).
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Many proteins appear across multiple groups, reﬂecting the
multifunctional nature of most proteins.
ELISA of alpha-1-acid glycoprotein
ELISA assay of alpha-1-acid glycoprotein conﬁrmed signiﬁcant
upregulation of expression in delirium CSF relative to AD subjects
(P= 0.026 using a two-tailed t-test, assuming unequal variances).
Mean values for delirium and AD subjects were 277.85 μgml− 1 (s.
e.m. 19.51, n= 12) and 207.44 μgml− 1 (s.e.m. 22.81, n= 18),
respectively.
Regression analyses; iTRAQ ratios vs cognition or delirium severity
scores
To determine whether there would be any relationship between
the 89 proteins identiﬁed in all three iTRAQ experiments (both
Sydney and Edinburgh study groups), and level of cognitive
impairment or delirium severity, regression analysis of iTRAQ ratio
vs MMSE, APACHE score and delirium index were performed
(Table 3). Several proteins had signiﬁcant associations with
cognitive level as measured by the MMSE score and/or the
APACHE III disease severity measure (31 proteins in total). When
this subset was processed using the STRING v9.05 bioinformatics
tool, the granin cluster increased in number of component
Figure 2. (a) Pathway analysis (STRING v9.05) of 39 proteins signiﬁcantly dysregulated in the CSF of subjects with mild or moderate delirium
relative to the mild AD control with no delirium. Subjects from both the Sydney and Edinburgh Delirium Studies were used. These are a subset
of proteins listed in Supplementary Table 4, which are dysregulated in at least 4 out of 17 delirium patients. The STRING MCL clustering tool35
was used to identify up to four clusters in this data set (clustered proteins are marked in same colour circles), and include; chromogranin and
secretogranin, apolipoproteins, clotting factors and regulatory proteins. The protein acronyms were as provided by the ProteinPilot software,
which uses the gene symbol nomenclature based on the Guidelines for Human Gene Nomenclature36 and http://www.genenames.org/
guidelines.html. (b) Pathway analysis (STRING v9.05) of proteins whose iTRAQ ratio is signiﬁcantly correlated with MMSE score (regression
analysis P-values are shown in Table 3). Delirium and normal control subjects from both the Sydney Delirium and Edinburgh Studies were
used for the regression analysis. The STRING MCL clustering tool was used to identify up to four clusters in this data set. (c) Theoretical model
of the relationship between proteomic changes and delirium pathophysiology. The proteins shown on this schematic are the signiﬁcantly
dysregulated proteins listed in Tables 2 and 3. CSF, cerebrospinal ﬂuid.
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proteins (Figure 2b), whereas other clusters either diminished
considerably in size or disappeared altogether.
DISCUSSION
Proteomics of delirium
Our current work is the ﬁrst iTRAQ quantitative proteomics
analysis of delirium CSF. More than 270 proteins were identiﬁed
with a high level of conﬁdence. Of these, about 10% had
dysregulated protein expression levels in 50% or more of delirium
subjects relative to the mild AD neurological control group. In
total, 26 proteins were identiﬁed with dysregulated protein
expression in at least six out of 12 delirium subjects from the
Sydney Delirium Study (Supplementary Table 3). This relatively
modest percentage of the CSF proteome dysregulated by disease
is typical in proteomics studies with a case–control design, where
5–20% dysregulation is common. It is important to note that out
of the dysregulated proteins subset, about 58% were identiﬁed in
only one to three subjects, and only 12% were identiﬁed in eight
or more delirium subjects (Figure 1). Several functional clusters of
proteins were identiﬁed in the subset of proteins dysregulated in
eight or more subjects. These included apolipoproteins and
chromogranin/secretogranins (downregulated in most delirium
subjects) and inﬂammation-related proteins (mostly upregulated
in delirium). The Sydney Delirium Study also included a
neurological comparison group (moderate AD), and interestingly,
the majority of proteins which were dysregulated in delirium were
unaffected in moderate AD relative to the mild AD control group.
The inference we make from this observation is that even though
the two disorders are related (that is, risk factors for each other),
on a molecular level there are distinguishing features. However
our cohort did not include severe AD, and it is possible that this
distinction might disappear with increasing AD severity. To
determine if the proteomic changes we observed would be
replicated in an independent study group, from a different
geographical region, a cohort of subjects from Edinburgh were
assessed. In addition to delirium subjects, the Edinburgh study
included control subjects who had also sustained a hip fracture
but did not develop delirium. There was no outpatient AD group
in the Edinburgh study. In the Edinburgh study, a total of seven
proteins had a signiﬁcantly dysregulated expression level in at
least three out of ﬁve delirium subjects. If the low normal group is
also included then 14 proteins were dysregulated in at least three
out of six subjects. There was considerable overlap with the
dysregulated proteins identiﬁed in the Sydney Delirium Study,
including apolipoproteins, chromogranin/secretogranins and
inﬂammation-related proteins.
Considering both Sydney and Edinburgh studies together, a
total of 16 proteins were identiﬁed, in which signiﬁcantly
dysregulated protein expression was observed in at least eight
out of 17 delirium subjects (Table 2). Of particular interest are
several protein functional clusters which emerged, including
proteins associated with inﬂammation, granins, apolipoproteins,
clotting factors, protease inhibitors and regulatory proteins.
Though members of these protein families have previously been
explored in neurodegenerative diseases, none have been studied
in the context of delirium.
Markers of inﬂammation
Signiﬁcant upregulation of alpha-1-acid glycoprotein was
observed in the majority of delirium subjects in both groups,
and also in an additional batch of CSF samples from the Sydney
study (n= 12 delirium, n= 18 AD), which were quantiﬁed by ELISA.
Upregulation of alpha-1-acid glycoprotein appears to be an
isoform-speciﬁc effect, as the iTRAQ study identiﬁed two isoforms,
ORM1 and ORM2, but only ORM1 was upregulated in the majority
of delirium subjects. Alpha-1-acid glycoprotein may be a speciﬁc
biomarker for delirium, or at least the effects of systemic illness on
the central nervous system, particularly as it does not appear to be
dysregulated in dementia, even though inﬂammation is also a well-
documented feature of AD. The ‘high normal’ control group subjects
of the Edinburgh study also do not have dysregulated expression of
ORM1. However these observations will require conﬁrmation with
analyses on larger numbers of subjects and further determination of
disease speciﬁcity by comparison with other neurodegenerative
conditions. Inﬂammation is thought to be one of the main causes of
delirium,37 consequently it is not surprising that in addition to alpha-
1-acid glycoprotein, the expression of several other acute-phase
proteins were observed to be dysregulated in the majority of
delirium subjects of both Sydney and Edinburgh studies, including;
alpha-2-macroglobulin, ﬁbrinogen, alpha-1-antitrypsin, alpha-1-
antichymotrypsin, transferrin, complement component 3 and
haptoglobin. Alpha-1-acid glycoprotein is of particular interest as
it is a steroid carrier, binds a variety of drugs, and could be a
potential target for drug treatment of delirium. Many of the acute-
phase markers have dysregulated expression in delirium (Table 2),
however none of them are signiﬁcantly associated with either
cognition (MMSE) or disease severity (APACHE III; Table 3), which
suggests that they may be indicators of inﬂammation rather than
speciﬁc to delirium pathophysiology.
Chromogranins and secretogranins
The majority of delirium subjects in both studies had signiﬁcantly
lower expression levels of chromogranin A, chromogranin B
(secretogranin I) and secretogranin III. The moderate AD-pooled
group (Sydney Delirium Study) had either downregulated or
unchanged granin expression levels whereas the normal controls
(Edinburgh Delirium Study) had upregulated granin levels relative
to the mild AD neurological control. The chromogranins and
secretogranins are a family of neuroendocrine secretory granule
proteins. Their normal physiological role is not well understood,
however, they are repositiories of a variety of neuropeptides with
hormone and neurotransmitter functions. They have not pre-
viously been identiﬁed in the context of delirium, however, their
potential roles in the diagnosis of neurodegenerative diseases are
attracting increased interest38–40 and more speciﬁc functions
being identiﬁed, including binding to the Aβ peptides, well known
for their role in AD neurodegeneration.41,42 Lower expression
levels of the granins observed in this study may relate to
disturbance of neurotransmission in delirium, providing evidence
for a long-standing delirium hypothesis.43 Three of the granins
(chromogranin A, secretogranin I and secretogranin III), which
were dysregulated (mostly downregulated) in at least 8 out of 17
delirium subjects (Table 2), were also positively associated with
MMSE score using regression analysis (Table 3). Furthermore
several additional granins and associated proteins (CHI3L1, SCG2,
SCG5, NCAM, PCSK1N) were signiﬁcantly associated with MMSE
and/or APACHE III even though their expression was dysregulated
in fewer than eight delirium subjects. Together these observations
suggest that lower granin levels might be associated with greater
delirium severity.
Apolipoproteins
Three apolipoproteins with dysregulated expression levels were
identiﬁed in both studies; ApoA1, ApoJ (clusterin) and ApoE. These
proteins were downregulated in the majority of delirium subjects.
In addition, ApoH (beta-2-glycoprotein 1) expression was sig-
niﬁcantly dysregulated in the majority of Sydney Delirium Study
subjects, however, expression levels varied considerably, with
both up- and downregulation observed with roughly equal
frequency. The apolipoprotein family are best known for their
role in the transport of lipids and cholesterol, being the main
protein components of HDL and LDL. They have been most
extensively studied in the context of cardiovascular disease, but
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also more recently in neurodegenerative diseases. In particular
ApoE has attracted considerable interest as the ApoEε4 allele is
the main genetic risk factor for late-onset AD,44 and other
neurodegenerative disorders.45 A recent meta-analysis suggested
an association between delirium and ApoEε4 allele,46 however,
the role of ApoEε4 allele in postoperative delirium is ambiguous,
with reports of both signiﬁcant association47 and absence of
association.48,49 Apart from the role of the different allelic forms,
altered CSF levels of apolipoproteins may impact on brain
metabolism, microvascular function and association with other
proteins which impact on brain pathology, such as amyloid plaque
in AD. The other apolipoproteins identiﬁed in this study have not
previously been studied in delirium, however, a sizable and
increasing literature is building on the role of ApoJ (clusterin) in
AD. ApoJ is typically found in HDL along with ApoA1. This
multifunctional protein may have roles in modulation of
inﬂammation, complement inactivation, Aβ binding and modula-
tion of neuronal plasticity and apoptosis.50 In view of its anti-
inﬂammatory and anti-apoptotic roles, its downregulation in
delirium CSF is likely to represent an adverse outcome. Apart
from a few speciﬁc cases, the broad spectrum of apolipoproteins
have not been extensively studied in neurodegenerative diseases
in general, though a recent study on plasma apolipoprotein levels
in mild cognitive impairment indicates that several apolipopro-
teins may have an impact on cognition and brain volumetrics in
this AD prodrome condition, including ApoA1, ApoE, ApoJ, ApoH
and ApoB/ApoA1 ratio.51
Although delirium is a multifactorial syndrome rather than a
single disease process, uncovering similar changes in the
proteome in delirium in two different clinical groups suggests
that there may be some common pathways in delirium. This has
implications for the possibility of discovering a diagnostic test and
speciﬁc treatment(s) for delirium. For example, it is possible that
some cases of delirium involve a predominantly inﬂammatory
aetiology and identifying such cases might facilitate the use of
anti-inﬂammatory drugs in that group.
Proteins signiﬁcantly associated with cognition and delirium
severity
Regression analysis of iTRAQ ratios vs MMSE or APACHE III scores
identiﬁed signiﬁcant associations of cognition and delirium
severity in 31 proteins, of which only ﬁve also had signiﬁcantly
dysregulated expression levels in the majority of delirium subjects
relative to the controls, these being; APOA1, APOE, SCG1, SCG3
and CHGA. The majority of proteins with signiﬁcant associations to
MMSE or APACHE III scores had dysregulated expression in fewer
than eight subjects, suggesting that changes to functionally
important proteins are subtle. Several of these may regulate;
neuronal differentiation (SERPINF1, CHI3L1, SPARCL1, NCAM1,
BCAN, NRCAM), hormone and small molecule binding (IGFBP7,
TTR, PTGDS), neuroendocrine secretion (PCSK1N, SCG2, SCG5) and
anti-oxidant defence (SOD1, SOD3). This outcome supports the
possibility that some proteins with signiﬁcantly altered expression
levels in delirium may not correlate well with clinical indicators of
cognition and disease severity. The increased size of the granin
cluster (Figure 2b) and other proteins, which correlate with MMSE
and/or APACHE scores, indicates that the converse may also be
true. However the subject numbers are low, and these possibilities
should be explored using larger group numbers and using
targeted approaches to increase statistical power.
Pathophysiology of delirium and the relevance of proteomic
changes
Delirium is a complex syndrome both in the variety of triggers or
risk factors that may initiate onset, as well as the diversity of
pathophysiological and cognitive features, which can include
inﬂammation, oxidative stress, reduced blood ﬂow, blood–brain
barrier and vascular dysfunction, confusion, cognitive impairment
and mood disturbance (Figure 2c). In this context, it is not
surprising to ﬁnd a diversity of proteomic changes representing
multiple biological processes, molecular functions and cellular
components. Less clear are how these changes orchestrate the
delirium syndrome, which are primary or secondary events, the
order in which changes occur or even if delirium can be deﬁned
by a single pathway.52 Furthermore, dysregulation in some of the
proteins we have identiﬁed is also reported in other age-related
neurodegenerative diseases, and may represent overlap of path-
ways and processes across different neurodegenerative condi-
tions. However our data does suggest some hypotheses and
allows us to make a number of predictions. One striking feature is
the uniform upregulation of the inﬂammatory protein ORM1 and
to a lesser extent other acute-phase proteins, while at the same
time few correlate with cognition (MMSE) or health status
(APACHE III). This suggests an important role for inﬂammation in
delirium, but it is probably not directly related to the cognitive
impairment aspect of the disorder. It may, however, be a trigger
for other events, one of which could be upregulation of protease
inhibitors, such as SERPINS A1 and A3 (Table 2). In fact
upregulation of complement, coagulation, ﬁbrinolysis and serpins
is typical of the host defence/stress response and we observe
upregulation of proteins in each of these groups (Table 2,
Supplementary Tables 3 and 4). Although a full understanding
of the role of protease inhibition in the brain remains to be
elucidated, a neuroprotective role of serpins has been
reported.53,54 Upregulation of protease inhibitors may be a
homeostatic response to inﬂammation, which if left unchecked
could cause neuronal apoptosis.55–57 By contrast, several of the
granin family proteins are downregulated in delirium subjects
(Table 2), and all of these, as well as a few others are signiﬁcantly
correlated with MMSE and some with APACHE III also (Table 3).
This does suggest a role for the granin family group in the
cognitive aspects of delirium, and given their precursor role for a
variety of neuropeptides, this is not too surprising.38 Some of
these peptides, such as secretoneurin and secretogranin I (CHGB)
proteolytic fragments, may regulate neurotransmitter levels. We
suggest that the lower granin expression levels that we observe
imply neurotransmitter deregulation, supporting one of the most
popular theories of delirium aetiopathology. CHGA and CHGB
both promote secretory granule biosynthesis, which are the main
extracellular storage vesicles for catecholamines. Lower CHGB
expression level in knockout mice results in fewer catecholamine
storage vesicles and unregulated catecholamine release into
plasma.58 Furthermore, expression of granin-related neuropep-
tides may be further compromised as a side effect of SERPIN
protease inhibitor upregulation, potentially restricting release of
neuropeptides from their granin precursors. In other words,
protease inhibition may protect neurons from inﬂammation-
related apoptosis, but as an unwanted side effect compromise
granin processing. Interestingly, a number of proteases as well as
protease inhibitor enzymes are correlated with MMSE scores
(Table 3; SERPINs F1 and G1, CST3, PCSK1N, B3GNT1) suggesting a
direct role in cognitive function. This hypothetical model predicts
that the level of granin-derived peptides will be lower in the CSF
of delirium patients. Altered neurotransmitter levels which have
been reported in the delirium literature6 may then partly be due
to lower levels of granins, granin-derived neuropeptides and
upregulation of protease inhibitors. Lower levels of several
apolipoproteins are also observed in the majority of delirium
subjects (Table 2), and may occur in parallel with downregulation
of the granins, as both protein groups are likely to be constituents
of neurosecretory granules. However the apolipoproteins subserve
diverse roles (Figure 2c and Supplementary Tables 5 and 6), and
may also be contributing to vascular changes reported in delirium,
or to neuronal plasticity/axonal regeneration.
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Limitations
With 17 CSF samples from delirium subjects in total, ours is a
relatively small study and there would be value in terms of
statistical power in undertaking additional work involving higher
subject numbers. In this study we have employed a neurological
control group (mild AD), and an additional normal control group
should be included in future work. Furthermore in this discovery
proteomics study, we are reporting relative expression changes.
Future work should include targeted analyses for absolute
quantiﬁcation such as ELISA or mass spectrometric multiple
reaction monitoring approaches. Our two studies also use
different methods to ascertain delirium. This can be considered
both a limitation and a beneﬁt; a limitation in that it presents a
mismatch between the studies and a beneﬁt in that the protein
changes that are common to both studies, given their differences,
are likely to be more robust biochemical indicators of delirium.
Summary
In this discovery proteomics project, we have quantiﬁed 4270
proteins in the CSF of delirium and control subjects, and across
two independent studies. Of these proteins, 16 were identiﬁed
with signiﬁcantly dysregulated protein expression level in the
majority of delirium subjects. Within this group of 16 proteins,
several family clusters were identiﬁed, including markers of
inﬂammation, protease inhibitors, chromogranins/secretogranins
and apolipoproteins. Furthermore some of these proteins and a
number of others are signiﬁcantly associated with cognition and
delirium severity, as assessed by regression analysis with MMSE or
APACHE III scores. These include the chromogranins/secretogra-
nins, SERPINS and apolipoproteins, and also proteins whose
functions include neuronal differentiation, hormone and small
molecule binding, neuroendocrine secretion and anti-oxidant
defence. This work offers some new protein targets that could be
used to further explore mechanisms of delirium, and provides a
list of potential biomarkers that could facilitate clinical work. Some
possibilities which might be considered include; (i) minimally
invasive surgical techniques to control inﬂammation and stress
response,59 (ii) anti-apoptotic treatments to minimize neuronal cell
damage60 and (iii) treatments to restore neurotransmitter levels.61
Furthermore, this study provides a good rationale for undertaking
larger scale work, and targeted analysis of some of the speciﬁc
proteins we have identiﬁed.
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